ABSTRACT Background: Carotenoids and vitamin C are thought to be associated with reduced cancer risk because of their antioxidative capacity. Objective: This study evaluated the associations of plasma carotenoid, retinol, tocopherol, and vitamin C concentrations and risk of breast cancer. Design: In a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort, 1502 female incident breast cancer cases were included, with an oversampling of premenopausal (n = 582) and estrogen receptor-negative (ER2) cases (n = 462). Controls (n = 1502) were individually matched to cases by using incidence density sampling. Prediagnostic samples were analyzed for a-carotene, b-carotene, lycopene, lutein, zeaxanthin, b-cryptoxanthin, retinol, a-tocopherol, g-tocopherol, and vitamin C. Breast cancer risk was computed according to hormone receptor status and age at diagnosis (proxy for menopausal status) by using conditional logistic regression and was further stratified by smoking status, alcohol consumption, and body mass index (BMI). All statistical tests were 2-sided. Results: In quintile 5 compared with quintile 1, a-carotene (OR: 0.61; 95% CI: 0.39, 0.98) and b-carotene (OR: 0.41; 95% CI: 0.26, 0.65) were inversely associated with risk of ER2 breast tumors. The other analytes were not statistically associated with ER2 breast cancer. For estrogen receptor-positive (ER+) tumors, no statistically significant associations were found. The test for heterogeneity between ER2 and ER+ tumors was statistically significant only for b-carotene (P-heterogeneity = 0.03). A higher risk of breast cancer was found for retinol in relation to ER2/progesterone receptor-negative tumors 
INTRODUCTION
Vegetables and fruit contain many putatively cancer-protective substances. For breast cancer, a recent meta-analysis of 15 prospective studies showed that high intake of fruit and of fruit and vegetables combined is associated with a weak breast cancer risk reduction. For vegetables only, no reduction in risk was found (1) . Because of measurement errors inherent to dietary questionnaires that were used in most of these studies (2) , protective effects may have been underestimated or small effects could have been missed. Even small effects can have a large impact on public health, leading to preventive dietary recommendations on a population scale.
Blood concentrations of carotenoids and vitamin C are good biomarkers of vegetable and fruit consumption and provide better estimates of the concentration actually available to cells than dietary questionnaires (3) (4) (5) (6) . Besides, carotenoids and vitamin C are thought to have cancer-protective capacities themselves (7) (8) (9) (10) . Recently, blood concentrations of 6 carotenoids were studied in relation to breast cancer risk in a meta-analysis of 15 prospective studies (11) . Higher concentrations of total carotenoids, a-carotene, b-carotene, and lutein were found to be statistically significantly associated with lower breast cancer risk. Another pooled analysis of 8 prospective studies, examining circulating carotenoids, found similar results and, in addition, statistically significant inverse associations for lycopene (12) . Blood concentrations of vitamin C have been studied in only one nested case-control study of limited size (13) , with no suggestion for a protective association.
Several prospective studies suggested that fruit and vegetable consumption and dietary carotenoid intake are more strongly related to estrogen receptor-negative (ER2) 45 than to estrogen receptor-positive (ER+) breast cancer (14) (15) (16) (17) (18) and more strongly to premenopausal than to postmenopausal breast cancer (1, 19) . The pooled analysis mentioned above (12) showed that inverse associations between b-carotene concentrations and breast cancer risk were statistically significantly stronger for ER2 than for ER+ breast cancer.
The aim of our study was to evaluate prediagnostic plasma concentrations of carotenoids and vitamin C in relation to subsequent risk of incident breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We also included tocopherol and retinol as was done in comparable studies (6, (20) (21) (22) (23) (24) (25) . The unique features of this investigation are its large sample size, allowing oversampling of premenopausal and ER2 breast cancer cases, and its long duration of follow-up, together with the fact that it includes participants from northern to southern Europe, spanning a wide range of vegetables and fruit consumption and related plasma biomarkers.
METHODS

EPIC cohort
EPIC is an ongoing multicenter, prospective cohort study primarily designed to investigate the relation between nutrition and cancer. The total EPIC cohort consists of 521,468 participants recruited from 23 centers in 10 European countries: Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom. Enrollment took place between 1992 and 1998. Further details have been described previously (26) .
Study participants
Eligible cases were all first primary incident, histologically confirmed (invasive) breast cancer cases identified by follow-up based on population cancer registries in most countries. For France, Germany, and Greece, a combination of methods was used, including health insurance records, cancer and pathology registries, and active follow-up through study participants and their next of kin.
Details on case and control selection have been described previously (27) . In short, of all breast cancer cases (n = 5458) diagnosed before 2005, 1502 cases (invasive breast cancer with blood samples available) and 1502 controls were selected. Our study was designed to include an oversampling of premenopausal and ER2 breast cancer cases. Age at diagnosis was used as a proxy for menopausal status at the time of breast cancer diagnosis (#50 compared with .50 y of age at diagnosis for 1 pre-and postmenopausal, respectively). All premenopausal cases (#50 y, n = 582) that were identified at the time of the study (irrespective of their ER2 status) were selected. From the postmenopausal cases (.50 y), all ER2 cases (n = 462) and an approximately equal sample from ER+ cases (n = 458) were selected. The ER+ cases were characterized by the same distribution of country and year of diagnosis as the ER2 cases, whereas apart from these criteria, their selection was random. Controls were selected by using an incidence density sampling design and further matched by study center, age (within 1 y), menopausal status at recruitment, use of exogenous hormones, phase of menstrual cycle, fasting status at blood collection, and time of blood collection (61 h) (27) .
All participants gave written informed consent. The study was approved by the local ethics committees in the participating centers and by the International Agency for Research on Cancer ethical review committee.
Laboratory assays
Details on laboratory analysis have been described earlier (28) . In brief, each batch contained 80 plasma samples, 2 3 39 for matched case-control pairs, which were analyzed in the same batch and in random order to minimize errors from batch-tobatch variations, and 2 quality control (laboratory) samples. Laboratory technicians were blinded to the case-control status of all samples. For this study, plasma samples were used that had not been thawed previously. Intrabatch and interbatch CVs were 2.8% and 8.7% for vitamin C, 9.1% and 13.2% for a-carotene, 5.6% and 10.9% for b-carotene, 3.7% and 9.1% for b-cryptoxanthin, 6.7% and 13.9% for lutein, 9.9% and 11.3% for lycopene, 11.3% and 21.9% for zeaxanthin, 2.7% and 6.9% for retinol, 2.5% and 8.2% for a-tocopherol, and 2.5% and 6.8% for g-tocopherol, respectively.
Carotenoids, retinol, and tocopherols
Plasma samples (200 mL) were analyzed for a-carotene, b-carotene, b-cryptoxanthin, lutein, lycopene, zeaxanthin, retinol, a-tocopherol, and g-tocopherol. The National Institute for Public Health and the Environment (Bilthoven, Netherlands) conducted the analysis. This analysis was done by using HPLC (using an HPLC column, 250 3 4.6 mm, ChromSpher 5 mm C18; Varian Assoc.), following a method based on that of Steghens et al. (29) .
Vitamin C
Plasma vitamin C was measured with a colorimetric assay on an LX20-Pro autoanalyzer (Beckman-Coulter).
Statistical analysis
Descriptives of all analytes were compared between cases and controls. Differences in means 6 SDs were tested by using paired t tests, and if variables were not normally distributed, they were log-transformed and geometric means were calculated. Spearman's rank correlation coefficient was used to assess the correlation between all individual analytes.
ORs and 95% CIs for ER+ and ER2 breast cancer in relation to plasma concentrations of all analytes were calculated with conditional logistic regression models, stratified by case-control set. Analyses were based on the quintile distribution among the controls (lowest quintile as reference category). Tests for linear trend across quintiles were performed by using median values of each quintile.
The final models were, in addition to conditioning on matching factors, adjusted for BMI (in kg/m 2 ), height, age at menarche, age at first full-term pregnancy, oral contraceptive pill use, hormone therapy use, smoking status, alcohol intake, total energy, saturated fatty acids, educational level, and season of blood collection (see Table 2 for units and categories), using indicator variables for missing data. Age at menopause (for postmenopausal women), physical activity [based on Cambridge Physical Activity Index (30)], and geographic region (northern/middle/southern Europe) were evaluated but not included in the final model because they did not change the relation with breast cancer risk and the first 2 variables were missing for several centers.
Analyses were also stratified by the combination of both receptors [ER+/progesterone receptor positive (PR+) compared with ER2/progesterone receptor negative (PR2)]. When further stratifying by age at diagnosis as a proxy for menopausal status, only strata with cases .50 y at diagnosis were large enough to draw conclusions on.
We assessed heterogeneity between the subtypes defined by receptor status by using a log-likelihood ratio test to compare conditional logistic regression models with and without interaction terms for subtype outcome (ER2 compared with ER+ and ER2/PR2 compared with ER+/PR+). Interaction terms were created by multiplying each subtype with the linear trend over the quintile score of analyte concentrations (31) .
Partial Pearson correlation coefficients (adjusted for age, BMI, and season of blood collection) were used to assess the correlation between all analytes and fruit and vegetable intake.
To diminish the influence of possible changes in food patterns or metabolic changes due to preclinical disease, we performed sensitivity analyses excluding cases whose blood samples were collected within 2 y before cancer diagnosis.
Finally, we examined the modifying effect of smoking status (never/past compared with current), alcohol consumption (continuous, g/d), and BMI (continuous) on the relations between plasma analyte concentrations on breast cancer risk, because a protective effect of high plasma antioxidant concentrations could be hypothesized to be stronger in women with high amounts of oxidative stress, caused by smoking and alcohol consumption (19, (32) (33) (34) (35) , and lower BMI might have stronger protective effects (12) . The analyses were performed with conditional logistic regression analyses by using interaction terms with all individual analytes (tertile distribution).
Two-sided P values ,0.05 were considered statistically significant. All analyses were performed by using SPSS 20 (SPSS Inc.) and SAS 9.2 (SAS Institute).
RESULTS
Baseline characteristics of cases and controls and their plasma concentrations of carotenoids, retinol, tocopherols, and vitamin C are shown in Tables 1 and 2, respectively. In breast cancer cases, time between blood donation and diagnosis was 4.1 y, on average. Most characteristics were equally distributed, which is partly due to the matching procedure. Because of failure of the PLASMA ANTIOXIDANTS AND RISK OF BREAST CANCER laboratory method or not enough sample available, there were 5 cases and 1 control with missing values on vitamin C, 28 cases and 22 controls on a-tocopherol and g-tocopherol, and 30 cases and 22 controls on all other analytes with missing values.
Spearman correlation coefficients between individual analytes are shown in Supplemental Table 1 . The highest correlation was observed between a-carotene and b-carotene (r = 0.69). Spearman correlations for plasma vitamin C, b-carotene, retinol, and the sum of a-and g-tocopherol with their dietary counterparts (vitamin C, b-carotene, and vitamins A and E) were low (0.13, 0.22, 0.14, and 20.18, respectively; data not shown).
The breast cancer risk associated with plasma concentrations of all analytes is shown in Table 3 for ER2 and for ER+ breast cancer. Risk of ER2 breast cancer was 39-59% lower for women in the highest quintile (quintile 5) compared with lowest quintile (quintile 1) in the adjusted analysis for plasma concentrations of a-carotene (OR: 0.61; 95% CI: 0.39, 0.98; P-trend = 0.02) and b-carotene (OR: 0.41; 95% CI: 0.26, 0.65; P-trend = 0.002). Results for retinol (OR: 1.65; 95% CI: 0.97, 2.81) showed a higher risk of ER2 breast cancer that was borderline statistically significant (P-trend = 0.08). The other analytes were not statistically associated with ER2 breast cancer. For ER+ tumors, no statistically significant associations were found, but the test for heterogeneity between ER2 and ER+ tumors was only statistically significant for b-carotene (P-heterogeneity = 0.03).
Separate analyses by ER/PR status ( Figure 1 ) indicated a protective effect of vitamin C in relation to ER+/PR+ breast cancer (OR: 0.64; 95% CI: 0.35, 1.17; P-trend = 0.04). In relation to ER2/PR2, a similar effect was observed, but here the P-trend was not statistically significant (P-trend = 0.16, Table 3 and Figure 1 (results not shown). Partial Pearson correlation coefficients between individual analyte concentrations and fruit and vegetable intakes are shown in Supplemental Table 2 . a-Carotene is most strongly related with root vegetables (r = 0.25), b-carotene with total and root vegetables (both r = 0.14), vitamin C with total and root vegetables (both r = 0.07), and zeaxanthin with leafy vegetables (r = 0.24). Retinol is inversely correlated with leafy vegetables (r = 20.20).
Sensitivity analyses were conducted excluding 341 cases whose blood samples were collected within 2 y before cancer diagnosis. Results were quite similar to the analysis including these cases. For ER2 breast cancer, in quintile 5 compared with quintile 1, this was a-carotene (OR: 0.73; 95% CI: 0.44, 1.22; P-trend = 0.14), b-carotene (OR: 0.48; 95% CI: 0.28, 0.81; P-trend = 0.03), and retinol (OR: 1.69; 95% CI: 0.93, 3.10; P-trend = 0.13).
Interaction terms for smoking status, alcohol consumption, or BMI (Supplemental Table 3 ) were for all analytes (based on a tertile distribution) not statistically significant.
DISCUSSION
To our knowledge, this is the largest nested case-control study to date of plasma carotenoids as well as retinol, tocopherols, and vitamin C in relation to hormone receptor-specific breast cancer risk.
For ER2 breast cancers, statistically significant associations were found for plasma a-carotene and b-carotene, leading to a 39-59% reduction in breast cancer risk.
Our results are largely in agreement with those of the pooled analysis of 8 prospective studies (12) . Their risk estimates for ER2 breast cancer (highest compared with lowest quintile) were OR = 0.61 for a-carotene and OR = 0.52 for b-carotene; ours were OR = 0.61 and OR = 0.41, respectively. Another pooled analysis of 18 prospective studies on dietary carotenoid intake also showed inverse associations of a-carotene, b-carotene, and lutein/zeaxanthin intake being primarily present in relation to ER2 but not to ER+ breast cancer (18) . This was also the case for vegetable consumption in a recently published large pooled analysis (36) . Two recent nested case-control studies on carotenoids and breast cancer subtypes did not observe heterogeneity between ER2 and ER+ tumors, but the number of ER2 breast cancers was much lower (n = 56 and n = 292, respectively) than in our study (37, 38) . The inverse associations found for ER2 breast cancer support the idea that the effect of antioxidants could be easier to detect in less hormone-dependent breast cancers, whereas for more hormone-dependent breast cancers, this effect might be "overshadowed" by the strong influence of hormonal factors (39) .
Unexpectedly, we observed higher risk ER2/PR2 breast cancer for women in the upper quintiles of zeaxanthin and retinol concentrations. These positive associations were not present in relation to ER+/PR+ breast cancer. Other nested case-control studies did not observe this relation (6, (20) (21) (22) (23) (24) (25) , although some describe a positive nonsignificant association with retinol (21, 22, 40). However, none was able to distinguish between receptorspecific breast cancer subtypes. The increased ER2/PR2 breast cancer risk in relation to higher concentrations of retinol could be due to the fact that retinol, in contrast to carotenoids and vitamin C, is merely derived from animal sources, although we have no reason to think this would pertain to ER2/PR2 breast cancer only. We do not have an explanation for the increased risk of ER2/PR2 breast cancer for women with high zeaxanthin concentrations. This has not been found in other studies or in relation to other cancers and could also be a chance finding.
We did not observe modification of the carotenoid-breast cancer associations by smoking, alcohol consumption, or BMI, as some earlier studies did (6, 12, 22, 25) . For example, some other studies showed stronger effects of high carotenoid concentrations in current smokers (12) . One explanation might be that the antioxidative effect of vitamin C is not visible in smokers because there is an overload of oxidative stress caused by smoking (also depleting vitamin C concentrations).
Our study has some limitations and strengths that deserve further discussion to help interpret our findings. We only have a single measurement of biomarkers available, and changes in long-term exposure and also day-to-day variation may have diluted the results. Daily variation was taken into account in part by matching on time of blood collection, fasting status, and adjusting for season. Moreover, repeatability studies on these biomarkers in blood samples collected up to 11 (vitamin C) to 15 y (retinol, a-and b-carotene) suggest that single measurements are reasonable estimators and representative to use as a predictor and suitable for assessment as risk factors (40) (41) (42) . The (higher as well as lower) differences in plasma concentrations of the investigated carotenoids compared with other studies investigating plasma analytes (20) (21) (22) (23) (24) (25) might be related to laboratory differences, because in a study investigating another sample of the EPIC population but using different laboratory techniques, lower concentrations of plasma carotenoids were observed in general (3). Because carotenoids are fat soluble, their concentrations in plasma may be influenced by type and amount of fat consumed. We did not measure and were therefore not able to adjust for plasma lipid concentration, which may have led to underestimation of the carotenoid associations. However, it should be noted that in nested case-control studies that did have this information available, adjustment did not materially alter the results (20, 43) .
PLASMA ANTIOXIDANTS AND RISK OF BREAST CANCER
Although our findings support the hypothesis that high concentrations of several carotenoids and vitamin C may protect against the development of hormone receptor-specific breast cancer, this does not necessarily mean that it helps to take dietary supplements (44) . The consumption of carotenoid-and vitaminrich food such as carrots as a dietary counterpart for a-carotene, carrots and leafy vegetables for b-carotene, and citrus fruits for vitamin C might lead to a possible lower (hormone receptorspecific) breast cancer risk. In general, effects of fruit and vegetable intake appear to be weak and largely confined to ER2 breast cancer (36) , but measurement errors inherent to dietary questionnaires may have diluted these effects. Also, we cannot exclude that other underlying lifestyle behaviors, genetic factors, or the availability of other bioactive compounds might be correlated with the biomarkers under study, leading to residual confounding (33, 45) . Other substances present in the same foods as vitamin C and carotenoids might be responsible for the beneficial effects too. The inverse association attributed to these vitamin concentrations may also be produced by a combination of bioactive compounds working synergistically together.
An important strength of this study is the inclusion of participants from 10 different countries with a large variation in consumption patterns. All plasma analytes were measured in the same laboratory and in samples collected well before breast cancer diagnosis, avoiding the potential modifying effect of cancer treatment and changes in lifestyle or dietary habits after the diagnosis of cancer. Further strengths of this study include large sample size, long follow-up time, and oversampling of ER2 and PR2 breast cancer subtypes, making it possible to evaluate these relatively infrequent but harmful breast cancer subtypes.
In conclusion, women with higher plasma concentrations of b-carotene and a-carotene are at lower breast cancer risk of ER2 breast cancer. FIGURE 1 ER/PR positive (n = 378) and ER/PR negative (n = 354) breast cancer ORs according to quintiles of plasma analytes. Stratified analysis based on conditional logistic regression analysis with linear trend tests across quintiles using median values of each quintile. P-heterogeneity across subtypes using a log-likelihood ratio test (with or without interaction terms). Diamonds represent ORs; lines represent 95% CIs. Lowest quintile represents reference category. ER2, estrogen receptor negative; ER+, estrogen receptor positive; PR2, progesterone receptor negative; PR+, progesterone receptor positive.
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